Animal Rights Advocate Gauri Maulekhi Raises Alarms Over India's Draft Animal Testing Norms Animal rights campaigner Gauri Maulekhi has strongly opposed the government's proposed draft regulations for laboratory animal testing, warning that diluted supervision could unleash severe animal cruelty, produce flawed clinical data, and harm India's international scientific reputation. Proposed regulatory revisions regarding the deployment of animals in medical and scientific experimentation have sparked a major national controversy. Gauri Maulekhi, an animal welfare advocate and trustee of People for Animals, has voiced grave reservations against the government's newly circulated draft regulations. Maulekhi contends that the proposed guidelines will dismantle existing protective frameworks, handing unrestricted authority to private and public laboratories while eroding the independent scrutiny vital for safeguarding experimental animals. In her assessment, scaling back monitoring standards threatens not only the welfare of defenseless creatures but also compromises the scientific validity and global standing of the Indian biomedical and pharmaceutical sectors. Institutional Independence Compromised by Internal Approval Panels The central contention within the draft framework lies in its decentralization of authorization, permitting research facilities to self-determine whether an experiment warrants official government clearance or can be sanctioned by their own in-house review committee. Under the established regulatory protocol, researchers must submit an exhaustive plan outlining the absolute necessity of living specimens, demonstrating why alternative methods cannot suffice and calculating the minimal head count required. The proposed draft shifts critical gatekeeping powers to an institutional committee comprising six members, four of whom will be internal personnel drawn from the same establishment, balanced against merely two external representatives. Because institutional staff constitute a clear majority, decisions risk being systematically swayed by commercial and corporate timelines rather than ethical standards. This conflict of interest is compounded by an amendment replacing unannounced, surprise spot-checks with pre-notified audits, granting laboratories ample advance notice to conceal violations and scrub non-compliant operating environments. Open-Market Animal Procurement and Compromised Medical Data The regulatory draft includes a contentious clause allowing research entities to source farm animals, birds, and aquatic species directly from open commercial markets whenever registered and certified breeders face inventory shortages. Animal welfare defenders caution that this loophole could spark rampant illicit catching of stray dogs, urban monkeys, and cattle from regional markets and trade fairs. Beyond the direct threat of trafficking, unmonitored animals gathered from random environments carry unknown pathogens, past traumas, and untreated infections. Introducing biologically uncontrolled specimens into preclinical trials inevitably skews experimental outcomes, producing corrupted datasets. When novel drug formulations and therapeutic treatments are manufactured based on distorted laboratory readings, the resulting pharmaceuticals pose grave clinical hazards to human patients. Wildlife Depletion and Habitat Disruption Another problematic aspect highlighted in the draft norms is the tacit latitude granted for extracting wild specimens directly from their natural habitats for clinical trials. Deploying nets, traps, and snares across forested belts endangers threatened fauna, precipitating disruptions across sensitive food chains and ecological balances. Wildlife conservation demands holistic protection of natural habitats rather than viewing individual species in isolation. Authorizing the capture of free-ranging wildlife to replenish laboratory stock introduces deep administrative contradictions and runs counter to established environmental statutes. Unmitigated Pain and Five-Year Repetitive Experimentation Under the proposed mandates, a single animal may be subjected to repeated, grueling experiments spanning up to five years. In orthopedic drug investigations, living rabbits routinely undergo forced bone fracturing so investigators can measure structural regeneration speeds under differing medicinal dosages. Earlier protocols mandated the compulsory administration of anesthetics and analgesics to numb agonizing trauma; however, the revised draft strips away essential stipulations guaranteeing pain relief. Similarly, in toxicology evaluations, chemical compounds are frequently administered until fifty percent of the experimental batch succumbs to lethal organ failure. Cosmetic and pharmacological compounds are also introduced directly into the eyes of rabbits to evaluate acute irritation and corrosive damage. Granting internal laboratory panels the authority to classify pain into mild, moderate, or severe brackets practically ensures that severe surgical suffering will be minimized on official balance sheets. Psychological Trauma Beyond Physical Brutality Physical mutilation represents only a fraction of the agony inflicted upon test subjects. Demonstrating the severity of current procedures, impact tests on vehicle helmets involve strapping fully conscious monkeys tightly into rigid chairs before subjecting their skulls to overwhelming mechanical force, deliberately fracturing the cranium to document exact mortality thresholds. Such protocols routinely disregard the cognitive awareness, distress, panic, and separation anxiety experienced by social mammals. Prolonged sensory isolation inside cramped metal cages, combined with enforced periods of food deprivation, inflicts deep psychological damage that persists well outside testing sessions. The Danger of Becoming an Offshore Testing Destination Rigorous regulatory regimes across the European Union have, since 2010, legally compelled researchers to substantiate why animal models cannot be substituted and to systematically minimize subject volumes. If India deregulates its domestic testing regime, multinational corporations facing stringent bans abroad could redirect their most aggressive, invasive trials to Indian facilities. While the global scientific community is rapidly embracing cutting-edge computational modeling, artificial intelligence platforms, cellular simulations, and organ-on-a-chip innovations to bypass biological testing, rolling back standards in India risks degrading the country into an ethical sanctuary for hazardous experimentation, damaging its global scientific prestige. Public Feedback Window Closes on November 5 Calling for proactive citizen participation, Gauri Maulekhi has urged researchers, healthcare specialists, civil organizations, and the wider public to register formal feedback on the draft guidelines before final notification. Stakeholder engagement remains a crucial check against rushed statutory changes that compromise both humane treatment and public health safety. Concerned individuals can submit formal representations and critical objections directly to the designated government portal via the official email address cpcsea-mef@gov.in prior to the November 5 deadline. What this means for you Revising norms for experimental animal testing directly impacts pharmaceutical safety, ecological balance, and human public health. • Drug Safety Risks: Utilizing unmonitored animals from open markets introduces erratic health variables into preclinical testing. Patients could face heightened exposure to dangerous pharmaceuticals formulated on compromised laboratory findings. • Wildlife Depletion: Allowing wild animal trapping for scientific protocols endangers native populations and disrupts local food chains. Rare and vulnerable forest fauna will face heightened exposure to commercial capture. • Global Scientific Credibility: Diluted oversight risks turning domestic labs into an outsourcing dump for hazardous overseas research. This could degrade international trust in Indian pharmaceutical innovations and scientific papers. • Public Action Window: Citizens and medical professionals retain the opportunity to submit formal objections until the November 5 cutoff. Engaging directly via the official email can help reshape final legislative standards. Why this happened The regulatory overhaul stems from efforts to expedite clearance timelines for biomedical research, which inadvertently bypasses independent oversight. • Demand for Expedited Approvals: Research entities have sought faster project sanctions, prompting administrators to delegate clearance duties to internal panels. This attempt to streamline paperwork has resulted in severe conflicts of interest. • Supply Shortfalls: Citing shortages of laboratory animals from certified breeding establishments, draftsmen permitted open-market animal procurement. This policy opened the door for stray and unregulated farm animals to be used in clinical tests. • Divergence from Modern Science: While Western jurisdictions mandate non-animal computational replacements, the proposed domestic draft seeks to sustain outdated animal models. Widespread pushback from animal advocacy bodies has forced the government to open a public feedback channel until November 5. Questions & Answers 1. Why has Gauri Maulekhi opposed the new draft regulations? She contends the proposed rules weaken regulatory accountability, increase severe animal suffering, and undermine human health through unreliable scientific data. 2. Who will compose the proposed in-house institutional committees? The committee will consist of six members, where four belong directly to the applicant institution and only two are external representatives. 3. What risks arise from sourcing animals from open markets? Stray or unmonitored animals often carry unknown diseases and infections, which severely compromises the reliability of drug testing outcomes. 4. What changes are proposed regarding pain relief during experiments? The draft eliminates key protective requirements that previously made pain relief and anesthetic administration mandatory during painful procedures. 5. What is the deadline for sending feedback on the draft rules? Citizens and stakeholders can submit formal feedback and objections to the government via cpcsea-mef@gov.in before November 5. https://trendkia.com/en/national/pashu-parikshana-ke-nae-draphta-niyamon-para-pashu-adhikara-karyakarta-gauri-maulekhi-ne-uthae-kare-savala-54073 TrendKia — Har trend, sabse pehle.